<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00551</drugbank-id>
  <drugbank-id>APRD00774</drugbank-id>
  <drugbank-id>EXPT01688</drugbank-id>
  <name>Acetohydroxamic acid</name>
  <description>Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly. It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.</description>
  <cas-number>546-88-3</cas-number>
  <unii>4RZ82L2GY5</unii>
  <average-mass>75.0666</average-mass>
  <monoisotopic-mass>75.032028409</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links>
      <link>
        <ref-id>L7</ref-id>
        <title>Link</title>
        <url>http://www.medicinenet.com/acetohydroxamic_acid-oral/article.htm</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>Teresio Tamietto, "Process for the preparation of an indole-3-acetohydroxamic acid." U.S. Patent US4186133, issued November, 1971.</synthesis-reference>
  <indication>Used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.</indication>
  <pharmacodynamics>Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly.</pharmacodynamics>
  <mechanism-of-action>Acetohydroxamic Acid reversibly inhibits the bacterial enzyme urease. This inhibits the hydrolysis of urea and production of ammonia in urine infected with urea-splitting organisms, leading to a decrease in pH and ammonia levels. As antimicrobial agents are more effective in such conditions, the effectiveness of these agents is amplified, resulting in a higher cure rate.</mechanism-of-action>
  <toxicity>Oral, rat: LD&lt;sub&gt;50&lt;/sub&gt; = 4.8gm/kg. Symptoms of overdose include anorexia, malaise, lethargy, diminished sense of wellbeing, tremor, anxiety, nausea, and vomiting.</toxicity>
  <metabolism>35-65% of oral dose excreted unchanged in urine (which provides the drug's therapeutic effect).</metabolism>
  <absorption>Well absorbed from the GI tract following oral administration.</absorption>
  <half-life>5-10 hours in patients with normal renal function</half-life>
  <protein-binding>No known binding</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as acetohydroxamic acids. These are organic compounds that contain a hydroxamic acid group carrying a methyl group attached to its carbon center.</description>
    <direct-parent>Acetohydroxamic acids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Carboxylic acid derivatives</subclass>
    <alternative-parent>Acetamides</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <substituent>Acetamide</substituent>
    <substituent>Acetohydroxamic acid</substituent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="german" coder="">Acethydroxamsaeure</synonym>
    <synonym language="english" coder="">Acetic acid, oxime</synonym>
    <synonym language="english" coder="">Acetohydroxamate</synonym>
    <synonym language="english" coder="inn/usan">Acetohydroxamic acid</synonym>
    <synonym language="english" coder="">Acetohydroximic acid</synonym>
    <synonym language="spanish" coder="">Acetyl hydroxyamino</synonym>
    <synonym language="english" coder="">Acetylhydroxamic acid</synonym>
    <synonym language="french" coder="">Acide acetohydroxamique</synonym>
    <synonym language="spanish" coder="">Acido acetohidroxamico</synonym>
    <synonym language="latin" coder="">Acidum acetohydroxamicum</synonym>
    <synonym language="english" coder="">AHA</synonym>
    <synonym language="english" coder="">Cetohyroxamic acid</synonym>
    <synonym language="english" coder="">Methylhydroxamic acid</synonym>
    <synonym language="english" coder="">N-Acetyl hydroxyacetamide</synonym>
    <synonym language="english" coder="">N-Acetylhydroxylamine</synonym>
    <synonym language="english" coder="">N-Hydroxyacetamide</synonym>
  </synonyms>
  <products>
    <product>
      <name>Lithostat</name>
      <labeller>Mission Pharmacal Company</labeller>
      <ndc-id/>
      <ndc-product-code>0178-0500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>250 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA018749</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Lithostat</name>
      <ingredients>Acetohydroxamic acid</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Mission Pharmacal</name>
      <url>http://www.missionpharmacal.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Mission pharmacal co</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Lithostat 250 mg tablet</description>
      <cost currency="USD">1.66</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Genito Urinary System and Sex Hormones</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hydroxy Acids</category>
      <mesh-id>D006880</mesh-id>
    </category>
    <category>
      <category>Hydroxylamines</category>
      <mesh-id>D006898</mesh-id>
    </category>
    <category>
      <category>Urease Inhibitor</category>
      <mesh-id/>
    </category>
    <category>
      <category>Urease Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Urologicals</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Enteric bacteria and other eubacteria</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>250 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="G04BX03">
      <level code="G04BX">Other urologicals</level>
      <level code="G04B">UROLOGICALS</level>
      <level code="G04">UROLOGICALS</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1am6</pdb-entry>
    <pdb-entry>1e9y</pdb-entry>
    <pdb-entry>1fwe</pdb-entry>
    <pdb-entry>1os2</pdb-entry>
    <pdb-entry>1utt</pdb-entry>
    <pdb-entry>1utz</pdb-entry>
    <pdb-entry>1y93</pdb-entry>
    <pdb-entry>2hu6</pdb-entry>
    <pdb-entry>2ow9</pdb-entry>
    <pdb-entry>2ozr</pdb-entry>
    <pdb-entry>3ba0</pdb-entry>
    <pdb-entry>3dpf</pdb-entry>
    <pdb-entry>3kec</pdb-entry>
    <pdb-entry>3lik</pdb-entry>
    <pdb-entry>3lil</pdb-entry>
    <pdb-entry>3ljg</pdb-entry>
    <pdb-entry>3lka</pdb-entry>
    <pdb-entry>4a7b</pdb-entry>
    <pdb-entry>4h9m</pdb-entry>
    <pdb-entry>4ubp</pdb-entry>
    <pdb-entry>5n5j</pdb-entry>
    <pdb-entry>5n5k</pdb-entry>
  </pdb-entries>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00551.pdf?1265922739</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The risk or severity of rash can be increased when Ethanol is combined with Acetohydroxamic acid.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>0.83</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.09e+02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>N-hydroxyacetamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>acetohydroxamic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>75.0666</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>75.032028409</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(=O)NO</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2H5NO2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>RRUDCFGSUDOHDG-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>49.33</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>16.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>6.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>8.94</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-5.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>1E+006 mg/L</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>90.5 °C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.59</value>
      <source>HANSCH,C ET AL. (1995)</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>8.7 (at 25 °C)</value>
      <source>SERJEANT,EP &amp; DEMPSEY,B (1979)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>49029</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>1990</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508546</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C06808</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00220</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>1913</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50099857</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164749213</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>HAE</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001277</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Acetohydroxamic_acid</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL734</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/acetohydroxamic-acid.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000334</id>
      <name>Urease subunit alpha</name>
      <organism>Enterobacter aerogenes</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A5119</ref-id>
            <pubmed-id>11101668</pubmed-id>
            <citation>Palinska KA, Jahns T, Rippka R, Tandeau De Marsac N: Prochlorococcus marinus strain PCC 9511, a picoplanktonic cyanobacterium, synthesizes the smallest urease. Microbiology. 2000 Dec;146 Pt 12:3099-107.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P18314" source="Swiss-Prot">
        <name>Urease subunit alpha</name>
        <general-function>Urease activity</general-function>
        <specific-function/>
        <gene-name>ureC</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.03</theoretical-pi>
        <molecular-weight>60304.12</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="548">Enterobacter aerogenes</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M36068</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>149337</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P18314</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>URE1_ENTAE</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.5.1.5</synonym>
          <synonym>Urea amidohydrolase subunit alpha</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010092|Urease subunit alpha
MSNISRQAYADMFGPTVGDKVRLADTELWIEVEDDLTTYGEEVKFGGGKVIRDGMGQGQM
LAADCVDLVLTNALIVDHWGIVKADIGVKDGRIFAIGKAGNPDIQPNVTIPIGAATEVIA
AEGKIVTAGGIDTHIHWICPQQAEEALVSGVTTMVGGGTGPAAGTHATTCTPGPWYISRM
LQAADSLPVNIGLLGKGNVSQPDALREQVAAGVIGLKIHEDWGATPAAIDCALTVADEMD
IQVALHSDTLNESGFVEDTLAAIGGRTIHTFHTEGAGGGHAPDIITACAHPNILPSSTNP
TLPYTLNTIDEHLDMLMVCHHLDPDIAEDVAFAESRIRRETIAAEDVLHDLGAFSLTSSD
SQAMGRVGEVILRTWQVAHRMKVQRGALAEETGDNDNFRVKRYIAKYTINPALTHGIAHE
VGSIEVGKLADLVVWSPAFFGVKPATVIKGGMIAIAPMGDINASIPTPQPVHYRPMFGAL
GSARHHCRLTFLSQAAAANGVAERLNLRSAIAVVKGCRTVQKADMVHNSLQPNITVDAQT
YEVRVDGELITSEPADVLPMAQRYFLF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0000664|1704 bp
ATGAGTAATATTTCACGCCAGGCCTATGCCGATATGTTCGGCCCCACCGTCGGCGACAAG
GTGCGCCTGGCAGATACCGAGCTGTGGATCGAGGTGGAGGACGATTTGACCACCTACGGG
GAAGAGGTCAAATTCGGCGGCGGCAAAGTGATCCGCGACGGCATGGGCCAGGGACAGATG
CTGGCCGCCGACTGTGTCGACCTGGTGCTCACCAACGCGTTGATCGTCGATCACTGGGGG
ATCGTTAAGGCCGATATCGGCGTGAAGGACGGCCGGATCTTCGCCATCGGCAAAGCCGGC
AACCCCGACATCCAGCCCAACGTCACCATCCCCATCGGCGCTGCGACGGAAGTGATCGCC
GCCGAAGGAAAAATTGTCACCGCCGGCGGGATCGATACCCATATTCACTGGATCTGTCCG
CAGCAGGCGGAAGAGGCGCTGGTCTCTGGCGTGACCACCATGGTCGGCGGCGGCACCGGC
CCGGCCGCGGGCACCCATGCCACCACCTGCACCCCGGGCCCGTGGTATATCTCACGCATG
CTGCAGGCGGCCGACAGCCTGCCGGTCAATATCGGCCTGCTGGGCAAGGGAAACGTTTCT
CAGCCGGATGCCCTGCGCGAGCAGGTGGCGGCAGGCGTTATTGGCCTGAAGATCCATGAG
GACTGGGGCGCCACCCCGGCGGCGATCGACTGTGCGTTAACCGTCGCCGATGAAATGGAC
ATCCAGGTCGCCCTGCACAGCGACACCCTGAATGAATCCGGTTTTGTGGAAGACACCCTC
GCCGCCATCGGCGGGCGCACCATCCACACCTTCCATACCGAAGGGGCCGGCGGCGGCCAT
GCGCCGGACATCATCACCGCCTGCGCCCACCCGAACATTTTGCCGTCGTCCACCAACCCA
ACGCTGCCCTACACCCTCAACACCATCGATGAACATCTCGATATGCTGATGGTCTGCCAC
CATCTGGACCCGGACATCGCCGAGGACGTGGCCTTTGCCGAGTCGCGCATTCGCCGGGAA
ACCATCGCTGCGGAAGACGTGCTGCACGATCTCGGCGCCTTCTCGCTCACCTCCTCCGAT
TCGCAGGCCATGGGCCGCGTCGGGGAAGTGATTCTCCGCACCTGGCAGGTGGCGCATCGC
ATGAAGGTGCAGCGCGGAGCGCTGGCGGAGGAGACCGGGGATAACGACAACTTCCGCGTG
AAGCGCTACATCGCCAAATACACCATCAACCCGGCGCTGACCCACGGCATCGCACACGAA
GTCGGATCCATTGAGGTGGGTAAGCTGGCTGACCTCGTGGTCTGGTCACCAGCCTTCTTC
GGCGTGAAACCGGCCACCGTGATCAAAGGCGGCATGATCGCCATCGCGCCGATGGGCGAT
ATCAATGCCTCTATTCCGACCCCGCAGCCGGTGCACTACCGCCCGATGTTTGGCGCGCTG
GGCAGCGCCCGCCATCACTGCCGCCTCACCTTCCTGTCGCAGGCGGCGGCAGCCAATGGC
GTTGCCGAGCGGCTGAACCTGCGCAGCGCGATCGCCGTGGTGAAAGGCTGCCGTACGGTG
CAGAAAGCCGACATGGTGCACAACAGTCTGCAGCCTAACATCACCGTCGACGCCCAGACC
TATGAGGTGCGGGTGGATGGCGAACTTATCACCAGCGAGCCGGCAGACGTTCTGCCGATG
GCGCAACGATATTTTCTGTTTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01979</identifier>
            <name>Amidohydro_1</name>
          </pfam>
          <pfam>
            <identifier>PF00449</identifier>
            <name>Urease_alpha</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nickel cation binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>urease activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urea catabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0001198</id>
      <name>Macrophage metalloelastase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12877</ref-id>
            <pubmed-id>16899369</pubmed-id>
            <citation>Mannino C, Nievo M, Machetti F, Papakyriakou A, Calderone V, Fragai M, Guarna A: Synthesis of bicyclic molecular scaffolds (BTAa): an investigation towards new selective MMP-12 inhibitors. Bioorg Med Chem. 2006 Nov 15;14(22):7392-403. Epub 2006 Aug 8.</citation>
          </article>
          <article>
            <ref-id>A12878</ref-id>
            <pubmed-id>15809432</pubmed-id>
            <citation>Bertini I, Calderone V, Cosenza M, Fragai M, Lee YM, Luchinat C, Mangani S, Terni B, Turano P: Conformational variability of matrix metalloproteinases: beyond a single 3D structure. Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5334-9. Epub 2005 Apr 4.</citation>
          </article>
          <article>
            <ref-id>A12879</ref-id>
            <pubmed-id>17269766</pubmed-id>
            <citation>Bertini I, Calderone V, Fragai M, Giachetti A, Loconte M, Luchinat C, Maletta M, Nativi C, Yeo KJ: Exploring the subtleties of drug-receptor interactions: the case of matrix metalloproteinases. J Am Chem Soc. 2007 Mar 7;129(9):2466-75. Epub 2007 Feb 2.</citation>
          </article>
          <article>
            <ref-id>A12880</ref-id>
            <pubmed-id>16959356</pubmed-id>
            <citation>Fukuda M, Peppas NA, McGinity JW: Floating hot-melt extruded tablets for gastroretentive controlled drug release system. J Control Release. 2006 Oct 10;115(2):121-9. Epub 2006 Jul 21.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P39900" source="Swiss-Prot">
        <name>Macrophage metalloelastase</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>May be involved in tissue injury and remodeling. Has significant elastolytic activity. Can accept large and small amino acids at the P1' site, but has a preference for leucine. Aromatic or hydrophobic residues are preferred at the P1 site, with small hydrophobic residues (preferably alanine) occupying P3.</specific-function>
        <gene-name>MMP12</gene-name>
        <locus>11q22.3</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-16</signal-regions>
        <theoretical-pi>8.98</theoretical-pi>
        <molecular-weight>54001.175</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7158</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>MMP12</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L23808</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>435970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1636</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P39900</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MMP12_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.24.65</synonym>
          <synonym>HME</synonym>
          <synonym>Macrophage elastase</synonym>
          <synonym>Matrix metalloproteinase-12</synonym>
          <synonym>ME</synonym>
          <synonym>MME</synonym>
          <synonym>MMP-12</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010834|Macrophage metalloelastase
MKFLLILLLQATASGALPLNSSTSLEKNNVLFGERYLEKFYGLEINKLPVTKMKYSGNLM
KEKIQEMQHFLGLKVTGQLDTSTLEMMHAPRCGVPDVHHFREMPGGPVWRKHYITYRINN
YTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDFHAFDGKGGI
LAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTY
KYVDINTFRLSADDIRGIQSLYGDPKENQRLPNPDNSEPALCDPNLSFDAVTTVGNKIFF
FKDRFFWLKVSERPKTSVNLISSLWPTLPSGIEAAYEIEARNQVFLFKDDKYWLISNLRP
EPNYPKSIHSFGFPNFVKKIDAAVFNPRFYRTYFFVDNQYWRYDERRQMMDPGYPKLITK
NFQGIGPKIDAVFYSKNKYYYFFQGSNQFEYDFLLQRITKTLKSNSWFGC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010835|Macrophage metalloelastase (MMP12)
ATGAAGTTTCTTCTAATACTGCTCCTGCAGGCCACTGCTTCTGGAGCTCTTCCCCTGAAC
AGCTCTACAAGCCTGGAAAAAAATAATGTGCTATTTGGTGAAAGATACTTAGAAAAATTT
TATGGCCTTGAGATAAACAAACTTCCAGTGACAAAAATGAAATATAGTGGAAACTTAATG
AAGGAAAAAATCCAAGAAATGCAGCACTTCTTGGGTCTGAAAGTGACCGGGCAACTGGAC
ACATCTACCCTGGAGATGATGCACGCACCTCGATGTGGAGTCCCCGATGTCCATCATTTC
AGGGAAATGCCAGGGGGGCCCGTATGGAGGAAACATTATATCACCTACAGAATCAATAAT
TACACACCTGACATGAACCGTGAGGATGTTGACTACGCAATCCGGAAAGCTTTCCAAGTA
TGGAGTAATGTTACCCCCTTGAAATTCAGCAAGATTAACACAGGCATGGCTGACATTTTG
GTGGTTTTTGCCCGTGGAGCTCATGGAGACTTCCATGCTTTTGATGGCAAAGGTGGAATC
CTAGCCCATGCTTTTGGACCTGGATCTGGCATTGGAGGGGATGCACATTTCGATGAGGAC
GAATTCTGGACTACACATTCAGGAGGCACAAACTTGTTCCTCACTGCTGTTCACGAGATT
GGCCATTCCTTAGGTCTTGGCCATTCTAGTGATCCAAAGGCCGTAATGTTCCCCACCTAC
AAATATGTTGACATCAACACATTTCGCCTCTCTGCTGATGACATACGTGGCATTCAGTCC
CTGTATGGAGACCCAAAAGAGAACCAACGCTTGCCAAATCCTGACAATTCAGAACCAGCT
CTCTGTGACCCCAATTTGAGTTTTGATGCTGTCACTACCGTGGGAAATAAGATCTTTTTC
TTCAAAGACAGGTTCTTCTGGCTGAAGGTTTCTGAGAGACCAAAGACCAGTGTTAATTTA
ATTTCTTCCTTATGGCCAACCTTGCCATCTGGCATTGAAGCTGCTTATGAAATTGAAGCC
AGAAATCAAGTTTTTCTTTTTAAAGATGACAAATACTGGTTAATTAGCAATTTAAGACCA
GAGCCAAATTATCCCAAGAGCATACATTCTTTTGGTTTTCCTAACTTTGTGAAAAAAATT
GATGCAGCTGTTTTTAACCCACGTTTTTATAGGACCTACTTCTTTGTAGATAACCAGTAT
TGGAGGTATGATGAAAGGAGACAGATGATGGACCCTGGTTATCCCAAACTGATTACCAAG
AACTTCCAAGGAATCGGGCCTAAAATTGATGCAGTCTTCTACTCTAAAAACAAATACTAC
TATTTCTTCCAAGGATCTAACCAATTTGAATATGACTTCCTACTCCAACGTATCACCAAA
ACACTGAAAAGCAATAGCTGGTTTGGTTGTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00045</identifier>
            <name>Hemopexin</name>
          </pfam>
          <pfam>
            <identifier>PF00413</identifier>
            <name>Peptidase_M10</name>
          </pfam>
          <pfam>
            <identifier>PF01471</identifier>
            <name>PG_binding_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>proteinaceous extracellular matrix</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metalloendopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>collagen catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix disassembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epithelial cell proliferation involved in wound healing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organic cyclic compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>wound healing, spreading of epidermal cells</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>